Trials / Completed
CompletedNCT01903694
Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 474 (estimated)
- Sponsor
- Centre Hospitalier Universitaire Dijon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Principal objective: to evaluate the effect of the combination pravastatin - sorafenib versus sorafenib alone on overall survival in patients with hepatocellular carcinoma developing on Child-Pugh A cirrhosis who are unsuitable for curative treatment. Secondary objectives: evaluate the effect of this treatment on progression-free survival, the time to progression, the time to treatment failure and quality of life (QLQ-C30 et FACT HEP)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib + Pravastatin | |
| DRUG | Sorafenib |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2013-11-01
- First posted
- 2013-07-19
- Last updated
- 2026-02-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01903694. Inclusion in this directory is not an endorsement.